. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Am J Transplant. 2018 Dec 6;19(4):1150–1159. doi: 10.1111/ajt.15148

Table 3:

Adjusted hazard of cardiovascular events and mortality by induction agent

	IL-2RA	ATG	AZM	None
CVE	Ref	0.98 (0.92–1.05)	1.01 (0.89–1.16)	1.06 (1.00–1.14)
Composite of mortality and CVE	Ref	0.93 (0.88–0.99)	0.91 (0.81–1.01)	1.02 (0.97–1.08)
All-cause mortality	Ref	0.94 (0.88–1.00)	0.96 (0.85–1.10)	1.01 (0.95–1.06)
CVE-related mortality	Ref	0.95 (0.81–1.12)	0.99 (0.70–1.38)	1.03 (0.89–1.18)

AZM: alemtuzumab, ATG: anti-thymocyte globulin, CVE: cardiovascular events, IL-2RA: IL-2 receptor antagonist